Salta alla navigazione principale Salta alla ricerca Salta al contenuto principale

Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network

  • Loredana Amoroso
  • , Victoria Castel
  • , Gianni Bisogno
  • , Michela Casanova
  • , Catalina Marquez-Vega
  • , Julia C. Chisholm
  • , François Doz
  • , Lucas Moreno
  • , Antonio Ruggiero
  • , Nicolas U. Gerber
  • , Franca Fagioli
  • , Pooja Hingorani
  • , Soledad G. Melcón
  • , Ruta Slepetis
  • , Nianhang Chen
  • , Yvan Le Bruchec
  • , Mathew Simcock
  • , Gilles Vassal
  • IRCCS Istituto Giannina Gaslini - Genova
  • Hospital Universitario La Fe
  • University of Padua
  • IRCCS Fondazione Istituto Nazionale per lo studio e la cura dei tumori - Milano
  • Hospital Universitario Virgen del Rocio
  • Royal Marsden NHS Foundation Trust
  • Université de Paris
  • Hospital Infantil Universitario Nino Jesus de Madrid
  • University of Zurich
  • Ospedale Infantile Regina Margherita
  • University of Texas MD Anderson Cancer Center
  • Vall d’Hebron University Hospital
  • Bristol-Myers Squibb
  • Institut Gustave Roussy

Risultato della ricerca: Contributo in rivistaArticolopeer review

Fingerprint

Entra nei temi di ricerca di 'Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network'. Insieme formano una fingerprint unica.
Ordina per

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science